검색어 : 통합검색[Habermann Norbert]
총 16건 중 16건 출력
, 2/2 페이지
-
11
- Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients
- Shi, Qian; Schmitz, Norbert; Flowers, Christopher; Ou, Fang-Shu; Cunningham, David; Pfreundschuh, Michael; Seymour, John F; Jaeger, Ulrich; Habermann, Thomas M.; Haioun, Corinne; Tilly, Hervé ; Ghesquieres, Herve; Merli, Francesco; Ziepert, Marita; Herbrecht, Raoul; Flament, Jocelyne; Fu, Tommy; Coiffier, Bertrand; Sargent, Daniel; Department of Health Sciences Research, Mayo Clinic, Rochester, MN; Asklepios Hospital St. Georg, Dep. Hematology, Oncology and Stem Cell Transplantation, Hamburg,, Germany; Department of Bone Marrow and Stem Cell Transplantation, Winship Cancer Institute of Emory University, Atlanta, GA; Department of Health Sciences Research, Mayo Clinic, Rochester, MN; Department of Medicine, The Royal Marsden Hospital, London and Surrey, United Kingdom; Innere Medizin I, Universitä t des Saarlandes, Homberg, Germany; Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Division of Hematology, Mayo Clinic, Rochester, MN; Unité Hé mopathies Lymphoï des, AP-HP Hô pital Henri Mondor, Cré teil, France; Henri Becquerel Centre, Université de Rouen, Rouen, France; Department of Hematology, Centre Hospitalier Lyon-Sud, Pierre-Benite, F; (Blood, v.128, 2016, pp.4196-4196)
-
12
- Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients
- Maurer, Matthew J; Habermann, Thomas M.; Shi, Qian; Schmitz, Norbert; Cunningham, David; Pfreundschuh, Michael; Seymour, John F.; Jaeger, Ulrich; Haioun, Corinne; Tilly, Hervé ; Ghesquieres, Herve; Merli, Francesco; Ziepert, Marita; Herbrecht, Raoul; Flament, Jocelyne; Fu, Tommy; Flowers, Christopher; Ou, Fang-Shu; Sargent, Daniel; Coiffier, Bertrand; Department of Health Sciences Research, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN; Department of Health Sciences Research, Mayo Clinic, Rochester, MN; Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St. Georg, Hamburg, Germany; Department of Medicine, The Royal Marsden Hospital, London and Surrey, United Kingdom; Innere Medizin I, Universitä t des Saarlandes, Homburg, Germany; Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Unité Hé mopathies Lymphoï des, AP-HP Hô pital Henri Mondor, Cré teil, France; Henri Becquerel Centre, Université de Rouen, Rouen, France; Department of Hematology, Centre Hospitalier Lyon-Sud, Pierre-Bé nite, France; Hematology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy; Institute for Med; (Blood, v.128, 2016, pp.3027-3027)
-
13
- Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)
- Maurer, Matthew J.; Jakobsen, Lasse H.; Schmitz, Norbert; Farooq, Umar; Flowers, Christopher R.; Brown, Peter de Nully; Thompson, Carrie A.; Frederiksen, Henrik; Cunningham, David; Jørgensen, Judit; Poeschel, Viola; Nowakowski, Grzegorz; Seymour, John F.; Merli, Francesco; Haioun, Corinne; Ghesquieres, Herve; Ziepert, Marita; Tilly, Herve; Salles, Gilles; Shi, Qian; El-Galaly, Tarec Christoffer C.; Habermann, Thomas M.; Department of Health Sciences Research, Mayo Clinic, Rochester, MN; Aalborg University Hospital, Aalborg, Denmark; Department of Medicine A, University Hospital Mü nster, Mü nster, Germany; Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA; Winship Cancer Institute, Emory University, Atlanta, GA; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Division of Hematology, Mayo Clinic, Rochester, MN; Department of Hematology, Odense University Hospital, Odense, Denmark; Department of Medicine, Royal Marsden Hospital, Surrey, United Kingdom; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Saarland University Medical School, Homburg, Germany; Division of Hematology, Mayo Clinic, Rochester, MN; Peter MacCallum Cancer Centre, Melbourne, Australia; Hematology unit, Azienda Unità Sanitaria Locale/IRCCS Reggio Emilia, Reggio Emilia, Italy; Clinical; (Blood, v.134, 2019, pp.400-400)
-
14
- Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma
- Maurer, Matthew J.; Jakobsen, Lasse H.; Mwangi, Raphael; Schmitz, Norbert; Farooq, Umar; Flowers, Cristopher R.; de Nully Brown, Peter; Thompson, Carrie A.; Frederiksen, Henrik; Cunningham, David; Jørgensen, Judit; Poeschel, Viola; Nowakowski, Grzegorz; Seymour, John F.; Merli, Francesco; Haioun, Corinne; Ghesquieres, Hervé ; Ziepert, Marita; Tilly, Hervé ; Salles, Gilles; Shi, Qian; El‐ Galaly, Tarec C.; Habermann, Thomas M.; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota; Aalborg University Hospital, Aalborg, Denmark; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota; Department of Medicine A, University Hospital Mü nster, Mü nster, Germany; Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, Iowa; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, Texas; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Division of Hematology, Mayo Clinic, Rochester, Minnosata; Department of Hematology, Odense University Hospital, Odens; (American journal of hematology, v.96, 2021, pp.599-605)
-
15
- Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
- Crump, Michael; Leppä , Sirpa; Fayad, Luis; Lee, Je Jung; Di Rocco, Alice; Ogura, Michinori; Hagberg, Hans; Schnell, Frederick; Rifkin, Robert; Mackensen, Andreas; Offner, Fritz; Pinter-Brown, Lauren; Smith, Sonali; Tobinai, Kensei; Yeh, Su-Peng; Hsi, Eric D.; Nguyen, Tuan; Shi, Peipei; Hahka-Kemppinen, Marjo; Thornton, Don; Lin, Boris; Kahl, Brad; Schmitz, Norbert; Savage, Kerry J.; Habermann, Thomas; Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä , Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los...; Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä , Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, Uni; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.34, 2016, pp.2484-2492)
-
16
- A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial
- Crump, Michael; Leppä , Sirpa; Fayad, Luis E; Lee, Je-Jung; Di Rocco, Alice; Ogura, Michinori; Hagberg, Hans; Schnell, Frederick; Rifkin, Robert M; Mackensen, Andreas; Offner, Fritz; Pinter-Brown, Lauren; Smith, Sonali M.; Tobinai, Kensei; Yeh, Su-Peng; Zhu, Jun; Hahka-Kemppinen, Marjo; Thornton, Donald; Shi, Peipei; Lin, Boris; Kahl, Brad S.; Schmitz, Norbert; Savage, Kerry J.; Habermann, Thomas M; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada,; Dept of Oncology, Helsinki University Central Hospital, Helsinki, Finland,; MD Anderson Cancer Center, The University of Texas, Houston, TX, USA,; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea,; Division of Hematology, Sapienza University, Rome, Italy,; Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan,; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden,; Central Georgia Cancer Care, Macon, GA, USA,; The US Oncology Network, Rocky Mountain Cancer Centers-SkyRidge, Lone Tree, CO, USA,; Dept. of Internal Medicine 5 - Hematology/Oncology, University of Erlangen-Nuernberg, Erlangen, Germany,; Department of Internal Medicine, University of Gent, Gent, Belgium,; University of California at Los Angeles, Santa Monica, CA, USA,; Department of Medicine, Section of Hematology/Oncology, The U; (Blood, v.122, 2013, pp.371-371)
12
QUICK MENU
